Recommended Articles
Fundraising

Resilience Care Raises €48M to Expand Its Remote Care Platform Beyond Oncology

By Angeled · November 6, 2026 · Fundraising
Resilience Care Raises €48M to Expand Its Remote Care Platform Beyond Oncology
Resilience Care Raises €48M to Expand Its Remote Care Platform Beyond Oncology

French healthtech company Resilience Care has raised €48 million from PSG Equity, a growth equity investor, to expand its remote patient monitoring platform beyond oncology into new areas of care. The round is one of the larger European healthtech financings of the week and underlines how quickly remote monitoring has moved from a niche oncology tool to a mainstream pillar of chronic-disease management.

What Resilience Care Does

Resilience Care builds a digital platform that lets care teams monitor patients remotely between appointments. Patients report symptoms, side effects, and quality-of-life measures through an app, and the platform flags deterioration early so clinicians can intervene before a problem becomes an emergency admission.

The company began in oncology, where the need is acute: cancer treatments such as chemotherapy and immunotherapy carry side effects that can escalate fast, and catching them early can keep a patient on treatment — and out of hospital. Remote monitoring in oncology has been studied for years, and the evidence base for structured symptom reporting is now well established: patients who report symptoms digitally tend to have them addressed sooner, and oncology teams can triage far more efficiently than with phone calls alone.

Why Expand Beyond Cancer?

The move beyond oncology is the strategic core of this raise. The same monitoring logic — structured patient-reported outcomes, alert thresholds, and clinician dashboards — applies to almost any chronic condition: heart failure, respiratory disease, diabetes, and post-surgical recovery all involve symptoms that worsen gradually and are cheaper to treat early than late.

For a platform company, disease-area expansion is also a commercial multiplier. Each new indication brings new hospital customers, new reimbursement conversations, and new data. It also changes the competitive frame: instead of competing only with oncology-specific tools, Resilience Care is positioning itself as a general remote-monitoring infrastructure layer for health systems.

The European Healthtech Context

European healthtech funding has been uneven in recent years, with investors favouring companies that already have clinical validation and real hospital deployments over earlier-stage ideas. A €48 million growth round fits that pattern: PSG Equity is a growth-stage investor, and a raise of this size typically follows proven traction rather than preceding it.

The timing also reflects a structural shift in European healthcare. Health systems across France and the wider EU face ageing populations, clinician shortages, and rising chronic-disease burdens. Remote monitoring is one of the few interventions that simultaneously reduces hospital load and improves patient experience, which makes it attractive to both providers and payers. Regulators have also become more comfortable with digital health tools, with reimbursement pathways for remote monitoring now existing in several European markets.

What the Money Is For

According to the announcement, the €48 million will fund expansion beyond oncology. In practice, that means product development for new disease areas, clinical validation work, hiring, and commercial expansion — likely both deeper penetration in France and entry into new European markets. Growth-stage healthtech raises of this size are typically split between building the product for new indications and funding the sales and implementation teams needed to deploy it in hospitals.

Why It Matters for Founders and Investors

For founders building in digital health, Resilience Care's trajectory is instructive. The company started narrow — one disease area, one clear clinical problem — earned trust with clinicians, and is now using that credibility to expand. That "wedge then widen" pattern is common among the healthtech companies that survive to growth stage: a broad platform pitch rarely wins hospital buyers, but a focused solution that demonstrably works in one department can become the entry point for the whole system.

For investors, the round is a reminder that European healthtech's centre of gravity has shifted toward companies with clinical evidence and deployed customers. Remote monitoring, once treated as a convenience feature, is increasingly framed as infrastructure — and infrastructure companies with recurring hospital contracts attract growth capital even in a cautious funding environment.

Angeled.com connects founders with investors.

Source: linkedin.com

Read Next